Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
10:42am, Wednesday, 02'nd Mar 2022
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
10:42am, Wednesday, 02'nd Mar 2022
JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
02:35pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.
Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should Know
03:00pm, Monday, 28'th Feb 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the posit
What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"
01:50pm, Monday, 28'th Feb 2022 Zacks Investment Research
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
04:09pm, Friday, 25'th Feb 2022 Zacks Investment Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
04:05pm, Friday, 25'th Feb 2022 Zacks Investment Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies
03:37pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
01:03pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders
Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%
04:54pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
01:03pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome Community Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
03:29pm, Monday, 14'th Feb 2022 Zacks Investment Research
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.
Here's Why Momentum in Catalyst (CPRX) Should Keep going
01:50pm, Friday, 11'th Feb 2022 Zacks Investment Research
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Momentum in Catalyst (CPRX) Should Keep going
10:00am, Friday, 11'th Feb 2022
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
03:00pm, Thursday, 10'th Feb 2022 Zacks Investment Research
The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
